Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Shares Gap Down - Time to Sell?

Key Points

• Shionogi & Co., Ltd. Unsponsored ADR shares experienced a gap down opening at $8.76, having closed at $9.05 the previous day, representing a decline of 1.2%.
• The company's earnings per share for the last quarter was reported at $0.16, surpassing analysts' expectations of $0.14, despite revenue falling short of estimates at $672.90 million.
• Shionogi holds a market cap of $15.21 billion with strong liquidity ratios, including a quick ratio of 6.13 and a current ratio of 6.63.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY - Get Free Report) gapped down prior to trading on Friday . The stock had previously closed at $9.05, but opened at $8.76. Shionogi & Co., Ltd. Unsponsored ADR shares last traded at $8.96, with a volume of 250 shares changing hands.

Shionogi & Co., Ltd. Unsponsored ADR Stock Down 0.1%

The company has a quick ratio of 6.13, a current ratio of 6.63 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $15.11 billion, a price-to-earnings ratio of 15.26, a P/E/G ratio of 2.03 and a beta of 0.20. The stock's fifty day moving average price is $8.70 and its 200-day moving average price is $8.30.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY - Get Free Report) last posted its quarterly earnings data on Monday, July 28th. The company reported $0.16 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.14 by $0.02. The business had revenue of $672.90 million during the quarter, compared to analyst estimates of $719.55 million. On average, sell-side analysts predict that Shionogi & Co., Ltd. Unsponsored ADR will post 0.66 earnings per share for the current fiscal year.

Shionogi & Co., Ltd. Unsponsored ADR Company Profile

Shionogi & Co, Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug.